IGF2BP3 and Wilson disease: After stratifying WD/DD LPS patients by IGF2BP3 expression, IGF2BP3+ was associated with worse survival in WD/DD LPS, mOS 7.7 vs. 21.5 years, p = 0.0234 (Figure 2B).